



PROTECH

Factsheet

**European
Trans* and
Non-binary
Individuals**

Inject PrEP to protect?

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



Maastricht University

What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.


The European Commission (EC) has authorized Apretude ® (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention.

It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.


This factsheet reports on data from the PROTECT Survey collected from trans* and non-binary individuals, who report being HIV-negative, N= 432.

Trans* & Non-Binary Individuals **432**

SURVEYS COLLECTED BY COUNTRY




AGE




Trans* & Non-Binary Individuals **432**

MIGRANT STATUS



RELATIONSHIP STATUS




An adequate representation of trans* & non-binary individuals in Europe




Trans* & Non-Binary Individuals **432**

CHEMSEX (in the past 6 months)



NUMBER OF SEXUAL PARTNERS (in the past 6 months)




Trans* & Non-Binary Individuals

432

Example of campaign image



HIV TESTING FREQUENCY



- More than every 6 months: 132
- Every 6 months: 92
- Less than once a year: 44
- Once a year: 71
- Never: 93


ORAL PrEP USE HISTORY & CURRENT PrEP REGIMEN

Naive: 290 Current: 110 Former: 32


Naive: 290	Current: 110	On-demand: 28
	Daily: 65	Mixed use: 17
	Former: 32	

Trans* & Non-Binary Individuals **432**

AWARENESS OF ORAL PrEP



CURRENT PREP USERS – ACCESS TO ORAL PREP



Barriers to oral PrEP use

- **19% of the trans* & non-binary individuals said:**
 - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- **26% of the trans* & non-binary individuals said:**
 - Their healthcare provider did not offer oral PrEP to them
- **20% of the trans* & non-binary individuals said:**
 - There was a waiting list at their healthcare provider for oral PrEP and the service was not available
- **20% of the trans* & non-binary individuals said:**
 - The procedure took too long to obtain oral PrEP when they needed it



Long-acting PrEP: interest and intention


65%

are interested in using LA-PrEP if it becomes available.*

59%

intend to use LA-PrEP if it becomes available.*

There were no significant differences found between the trans and non-binary groups



Summary & Contact Information

SUMMARY

- Trans* & non-binary individuals across Europe are aware of PrEP and have taken up oral PrEP
- Barriers to starting PrEP still exist
- Interest and intention to use LA-PrEP among trans* & non-binary individuals across Europe is high
- LA-PrEP may provide an opportunity for greater HIV prevention in Europe

CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas
Email: kai.jonas@maastrichtuniversity.nl
- Dr. Johann Kolstee
Email:
johann.kolstee@maastrichtuniversity.nl
- Maastricht University postal address
P.O. Box 616, 6200 MD Maastricht, The Netherlands